HOME >> BIOLOGY >> NEWS
Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury

Hawthorne, NY June 28, 2002 Acorda Therapeutics announced today that it has begun two Phase 3 clinical studies of its lead product, Fampridine-SR, in chronic spinal cord injury. The trials will evaluate the safety and efficacy of Fampridine-SR in the treatment of moderate-to-severe spasticity associated with chronic SCI. Spasticity, which affects up to 75% of people with chronic SCI, manifests itself as involuntary stiffness or contraction of muscles.

The studies will enroll a total of 360 patients at more than 70 of the leading spinal cord injury (SCI) clinical centers in the United States and Canada. Individuals who are interested in finding out about participating in these studies may call 866-206-2322, toll-free, weekdays from 9:00 a.m. (EDT) to 7:00p.m. (EDT)

"There is significant demand for new treatment options in chronic spinal cord injury, especially spasticity. Spasticity is a serious complication of SCI that frequently interferes with movement and daily activities, and can cause severe pain or injury," said Ron Cohen, MD, Acorda's President and Chief Executive Officer.

Fampridine ("4-aminopyridine", "4-AP") enhances conduction in damaged nerves, and is the first compound shown to restore some neurological function to people with SCI. Fampridine-SR is an oral, sustained-release formulation of fampridine, designed for twice-daily dosing. The drug restores nerve conduction by blocking exposed potassium channels in demyelinated nerve processes, or axons. Fampridine-SR is also in Phase 2 clinical trials to evaluate safety and efficacy in the treatment of symptoms associated with multiple sclerosis (MS).

In previous SCI clinical trials, administration of Fampridine-SR has been shown to reduce spasticity, and to improve sexual function and bowel and bladder control. The most common side effects observed with Fampridine-SR treatment have been pain, paresthesia, insomnia, dizziness, constipation, and nausea. At clin
'"/>


1-Jul-2002


Page: 1 2

Related biology news :

1. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
2. Acorda Therapeutics acquires CeNeS neuregulin products
3. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
4. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
5. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
7. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
8. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
9. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. Immerge BioTherapeutics announces identification of PERV receptor

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/18/2018)... ... October 18, 2018 , ... Drug toxicity is a pervasive issue in the ... and mitigated. Failure to recognize such toxicities during the course of drug development ... serious challenge to drug developers faced with an unforeseen drug withdrawal from the market. ...
(Date:10/18/2018)... Texas (PRWEB) , ... October 18, 2018 , ... ... closer to reality , Texas A&M receives USDA-APHIS deregulation approval , Writer: Kay ... flour to deliver protein to millions of people, a project to which Dr. ...
(Date:10/16/2018)... , ... October 16, 2018 , ... Our own cells ... discs in our spine. , So comments interventional spine and pain management specialist Jason ... enzymes and proteins, or stem cells harvested from a patient’s bone marrow are proving ...
Breaking Biology News(10 mins):
(Date:10/18/2018)... , ... October 18, 2018 , ... ... sequencing laboratory in the San Francisco Bay Area has received accreditation from the ... and patient safety. , Predicine received CAP accreditation for its Shanghai facility last ...
(Date:10/16/2018)... ... October 16, 2018 , ... uBiome, the leader in ... at the Biomedical Research Institute of Malaga, University Hospital Virgen of Victoria, Malaga ... to its Scientific Advisory Board. Joining the board of leading scientists and doctors ...
(Date:10/11/2018)... , ... October 10, 2018 , ... ... biotech community, announces the appointment of Wendy Nelson, PhD, as its new CEO. ... and R&D experience in the biotech industry. Most recently, Dr. Nelson was ...
(Date:10/5/2018)... , ... October 04, 2018 , ... ... Anacortes, Wash.-based nonprofit, with a grant to purchase a high-tech machine that turns ... washes ashore in Washington State. The organization then processes the usable plastic and ...
Breaking Biology Technology:
Cached News: